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Doxorubicin (DOX), an anthracycline drug widely 
used for the treatment of various cancers, causes a cu-
mulative dose-dependent cardiac toxicity that is char-
acterized by an irreversible cardiomyopathy and con-
gestive heart failure. The cardioprotective effect of 2.5, 
5, 7.5 and 10 mg/kg naringin (NIN) was studied in 
mice treated with 15 mg/kg DOX. The animals were 
killed 30 h after DOX treatment. The latter induced 
acute cardiotoxicity indicated by a significant elevation 
in glutamic pyruvic transaminase (GPT), glutamic ox-
aloacetic transaminase (GOT), creatine kinase (CK-
MB) and lactate dehydrogenase (LDH) in mice serum. 
Treatment of mice with NIN before DOX administra-
tion significantly reduced serum levels of GPT, GOT, 
CK-MB and LDH indicating that NIN protected 
against the DOX-induced cardiotoxicity. DOX induced 
a significant increase in the 8-OHdG DNA adducts and 
the PARP activity in the heart and liver of mice, 
whereas NIN treatment of mice before DOX admini-
stration significantly reduced 8-OHdG DNA adducts 
and PARP activity in the heart and liver. Similarly, 
NIN inhibited the DOX-induced decline in the glu-
tathione concentration, catalase and superoxide dismu-
tase activities and abated DOX-induced lipid peroxida-
tion in the heart and liver of mice. Intraperitoneal ad-
ministration of 1.25 mg/kg DOX significantly elevated 
survival of Ehrlich ascites carcinoma (EAC) bearing 
mice, whereas the combination of 10 mg/kg NIN with 
DOX did not alter the tumor cell growth, median sur-
vival time or average survival time of tumor bearing 
mice when compared to DOX treatment alone, indicat-
ing that NIN does not interfere with the antineoplastic 
activity of DOX. Our study demonstrates that naringin 
reduced the doxorubicin-induced cardiotoxicity, with-
out affecting its antineoplastic activity, which may be 
due to reduction in the DOX-induced 8-OHdG DNA 
adducts and PARP activity, increase in the antioxidant 
enzymes and alleviation of lipid peroxidation by nar-
ingin. 
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Introduction 
 
Anthracyclines constitute a major class of cytotoxic 
agents for the treatment of cancer. Among these, 
doxorubicin (DOX) a quinone-containing anthracy-
cline antibiotic, is an important anticancer drug used 
for treating a wide spectrum of human neoplasms in-
cluding Hodgkin’s and non-Hodgkin’s disease, soft 
tissue sarcoma, breast, ovarian, lung, bladder, thyroid, 
liver and stomach cancer, Wilm’s tumor, neuroblas-
toma as well as acute lymphoid leukemia (Carter 1975, 
Martin & McNally 1980, Weiss 1992). However, its 
clinical utility is limited due to dose-dependent cumu-
lative cardiotoxicity that includes electrocardiographic 
changes, arrhythmias, irreversible degenerative cardio-
myopathy and congestive heart failure (Minotti et al. 
2004, Tacar et al. 2013). DOX binds to nucleic acids, 
presumably by specific intercalation of the planar an-
thracycline nucleus with the DNA double helix 
(Gewirtz 1999). The anthracycline ring is lipophilic, 
but the saturated end of the ring system contains abun-
dant hydroxyl groups adjacent to the amino sugar, pro-
ducing a hydrophilic center. The molecule is ampho-
teric, containing acidic functions in the ring phenolic 
groups and a basic function in the sugar amino group. 
It binds to cell membranes as well as plasma proteins. 
Despite extensive research, the mechanism underlying 
the cardiac damage induced by DOX is still not com-
pletely understood. It has been reported that mitochon-
drial dysfunction and iron catalyzed free-radical pro-
duction (oxidative stress) leads to cardiotoxicity 
(DeAtley et al. 1999, Gewirtz 1999, Asensio-Lopez et 
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al. 2013), because the heart tissue has a limited de-
fense system and can not cope with the free radical 
induced toxicity of DOX (Mimić-Oka et al. 1999). 
DOX has been reported to be metabolically activated 
to a free radical state and interacts with molecular oxy-
gen to generate superoxide radicals (Powis 1989, Ol-
son & Mushlin 1990), that are generated through redox 
cycling of DOX in vivo. Superoxide radicals can react 
with hydrogen peroxide to form highly reactive hy-
droxyl radicals via the iron catalyzed Haber-Weiss re-
action. The secondarily derived hydroxyl radicals can 
cause protein and DNA damage and initiate lipid per-
oxidation (Halliwell & Gutteridge 1989). Increased 
lipid peroxidation, and enhanced free radical genera-
tion in the heart have been found to be the major cause 
of DOX induced cardiotoxicity (Olson & Mushlin, 
1990). Iron plays a crucial role in DOX-induced toxic-
ity, as the generation of oxygen free radicals is facili-
tated by the formation of DOX-iron complexes (Myers 
1998).  
 ROS can cause oxidative damage to both nu-
clear and mitochondrial DNA. The nature of DNA 
damage mainly includes base modification, deoxyri-
bose oxidation, strand breaks and DNA-protein 
crosslinks. Guanine is by far the most prevalent target, 
although adducts have been reported for all bases 
(Poirier et al. 2000). ROS react with heterocyclic bases 
in DNA and cause hydroxylation of guanine at the C-8 
position. This guanine base hydroxylation leads to the 
formation of 8-hydroxy-2'-deoxyguanosine (8-OHdG), 
which is a common base modification (Kasai & Nishi-
mura 1983). DOX has been reported to generate 8-
OHdG, an indicator of oxidative DNA damage, in HL-
60 and MCF-7 cells (Mizutani et al. 2003, Swift et al. 
2006, Coldwel et al. 2008). Increased levels of 8-
OHdG have been indicated in various pathophysiologi-
cal processes such as carcinogenesis, aging, cardiovas-
cular and degenerative diseases (Wu et al. 2004, Vala-
vanidis et al. 2009).  
 Poly (ADP-ribose) polymerase (PARP), also 
known as poly-(ADP ribose) transferase (pADPRT) or 
poly-(ADP ribose) synthetase (PARS), [EC 2.4.2.30] 
is an abundant nuclear enzyme in eukaryotic cells. It is 
activated by DNA strand breaks and initiates an energy
-consuming cycle by transferring ADP ribose units 
from NAD+ to nuclear proteins. This process results in 
rapid depletion of the intracellular NAD+ and ATP 
pools, slowing the rate of glycolysis and mitochondrial 
respiration and eventually leading to cellular dysfunc-
tion and death (Zingarelli et al. 1998, Burkart et al. 
1999, Szabo et al. 2004). Overactivation of PARP 
leads to tissue damage in various pathological condi-
tions associated with oxidative stress, including myo-
cardial reperfusion injury (Zingarelli et al. 1998, Sori-
ano et al. 2001a, b, Pacher et al. 2002), stroke 
(Eliasson et al. 1997), circulatory shock  (Oliver et al. 
1999, Liaudet et al. 2000, Szabo et al. 2005), autoim-
mune cell destruction (Burkart et al. 1999) and cardio-
vascular dysfunction (Soriano et al. 2001a, b, Pacher et 
al. 2002, 2006). Doxorubicin induces oxidative and 
nitrosative stress and, subsequently, overexpression of 
PARP in the rat or mice heart leading to cardiomyopa-
thy (Szenczi et al. 2005, Szántó et al. 2011, Lim 
2013). The excessive oxidative and nitrosative stress 
triggers DNA damage, overactivation of PARP, de-
crease in cellular NAD+ and can impair glycolysis, the 
Krebs cycle together with mitochondrial electron trans-
port, and will eventually reduce the ATP pool. This 
eventually leads to cell dysfunction and death by ne-
crosis (Pacher & Sazbo 2007). There is a close rela-
tionship between oxidative and nitrosative stress and 
PARP activation in doxorubicin-treated animals, as 
well as in humans undergoing doxorubicin anticancer 
therapy (Bachur et al. 2002, Pacher & Szabo 2008, 
Singal et al. 1997). The role of calcium in DOX-
induced cardiotoxicity has begun to unfurl. The cal-
cium overload in mitochondria triggers permeability 
changes in the latter, leading to alteration in its mem-
brane potential, mitochondrial swelling and increased 
permeability of its outer membrane, causing apoptosis 
of myocytes (Wallace 2007). PARP activation contrib-
utes to the development of the disturbances in cellular 
calcium handling that develop in the myocardium, in 
response to doxorubicin treatment (Orsolya et al. 
2005). PARP inhibitors have been found to provide 
benefit in clinical trials against BRCA mutant cancers 
that are unable to  repair DNA double strand breaks by 
homologous recombinant repair (Curtin & Szabo 2013, 
Do & Chen 2013). Similarly, PARP inhibitors have 
been reported to increase the effect of ionizing radia-
tion and certain chemotherapeutic drugs (Curtin & 
Szabo 2013). Recent reports indicate that PARP in-
hibitors are also active in homologous repair-sufficient 
tumors (Luo & Kraus 2012). 
 The use of antioxidants to prevent DOX-
induced toxicity has been advocated and strategies 
have been devised to prevent DOX-induced cardiotox-
icity without affecting its antitumor activity by com-
bining it with cardioprotectives and antioxidants 
(Singal et al. 1997). Dexrazoxane, a bisdi-
oxopiperazine compound is the clinically approved 
drug for the prophylaxis of DOX-induced cardiotoxic-
ity in cancer patients (Weiss 1992). The toxic potential 
of this agent (especially haemato and hepatotoxicities) 
encourages further investigation of new cardioprotec-
tants with lower toxicities. Therefore, a drug which 
can protect against the cardiotoxicity of DOX without 
compromising its antineoplastic activity is needed. 
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 In this regard, flavonoids are a class of natu-
rally occurring compounds with excellent iron chelat-
ing and radical scavenging properties (Kaiserová et al. 
2007) and are therefore of interest as possible modula-
tors of DOX-induced cardiotoxicity and genotoxicity. 
Naringin (naringenin 7-rhamnoglucoside), a grapefruit 
flavanone is present in most of the citrus species and 
has metal chelating, antioxidant, and free radical scav-
enging properties (Jagetia & Reddy 2011). It has been 
reported to offer some protection against mutagenesis 
and lipid peroxidation (Miyake & Shibamoto 1997, 
Jagetia et al. 2004, Jagetia & Reddy 2005, 2011). Nar-
ingin has been reported to inhibit human breast cancer 
cell proliferation and delay mammary tumorigenesis 
(So & Guthrie 1996). It has also been reported to re-
duce constitutive expression of tumor necrosis factor 
in walker’s carcinoma (Camargo et al. 2012). Naringin 
has been reported to protect cells against the radiation-
induced chromosome damage as well as iron and ra-
diation-induced oxidative stress (Nagaratnam et al. 
1999, Jagetia et al. 2003, 2004, Jagetia & Reddy 2002, 
2005, 2011). Treatment of mice with naringin has also 
been reported to reduce the tumor burden and tumor 
incidence in forestomach carcinoma (Jagetia & Reddy 
2004). However, a systematic evaluation of the effect 
of NIN on DOX-induced cardiotoxicity, 8-OHdG 
DNA adducts and oxidative stress in mice is lacking. 
Therefore, the present study was undertaken to obtain 
an insight into the effects of naringin on the doxorubi-
cin-induced cardiotoxicity in Swiss albino mice. 
 
Materials and Methods 
 
Chemicals 
Naringin was procured from Acros Organics Ltd, Geel, 
Belgium, whereas doxorubicin hydrochloride was ob-
tained from Biochem Pharmaceutical Industries, Mum-
bai, India. The DNA adducts estimation kit (8-OHdG 
Check ELISA Kit, Catalog # KOG-200SE) and PARP 
cellular ELISA kit (Catalog # QIA 105) were procured 
from Gentuar, Brussels, Belgium and Oncogene Re-
search Products, EMD Biosciences, Inc. La Jolla, CA, 
USA, respectively. All other chemicals were supplied 
by Merck India Ltd., Mumbai, India. 
 
Animal care and handling 
The animal care and handling were carried out accord-
ing to the guidelines issued by the World Health Or-
ganization, Geneva, Switzerland and INSA (Indian 
National Science Academy, New Delhi, India). Ten to 
twelve weeks old male Swiss albino mice weighing 30 
to 36 g were selected from an inbred colony main-
tained under the controlled conditions of temperature 
(23±2ºC), humidity (50±5%) and light (12 h of light 
and dark, respectively). The animals had free access to 
sterile food and water. Four animals were housed in a 
polypropylene cage containing sterile paddy husk 
(procured locally) as bedding throughout the experi-
ment. The study was approved by the Institutional Ani-
mal Ethical Committee of the Kasturba Medical Col-
lege, Manipal, India, where the study was carried out. 
 
Preparation of drugs & mode of administration 
Naringin (NIN) or doxorubicin hydrochloride (DOX) 
was freshly prepared in sterile double distilled water 
(DDW), immediately before use. The animals were 
injected with either 0.01 ml/g per body weight (b.wt.) 
DDW or various doses of NIN orally (p.o.) (Popper & 
Sons, Inc., New Hyde Park, NY, USA). 
 
Effect of NIN on DOX-induced cardiotoxicity 
The animals were divided into the following groups: a) 
NIN group: the animals of this group were orally ad-
ministered with 0, 2.5, 5, 7.5 or 10 mg/kg b. wt. of 
NIN once daily for 5 consecutive days. B) DDW and  
DOX group: the animals of this group received orally 
sterile double distilled water, once daily for 5 consecu-
tive days. One hour after the last administration, the 
animals of this group received a single injection of 15 
mg/kg b. wt. of DOX. C) NIN and DOX group: The 
animals of this group were orally administered with 
2.5, 5, 7.5 and 10 mg/kg b. wt. of NIN once daily for 5 
consecutive days followed by a single intraperitoneal 
injection of 15 mg/kg b. wt. of DOX one hour after the 
last treatment with NIN. A total of four animals (n = 4) 
were used in each group and a total of 40 animals were 
used for this experiment 
 
Estimation of serum enzymes 
The mice were killed by decapitation 30 h after DOX 
treatment (Abd et al. 2001). The blood was collected 
by cardiac puncture, the serum was separated by cen-
trifugation at 5000 rpm for 10 minutes and frozen at –
70°C for estimation of creatine kinase isoenzyme (CK-
MB), lactate dehydrogenase (LDH), glutamic pyruvic 
transaminase (GPT) and glutamic oxaloacetic transa-
minase (GOT) (Reitman & Frankel 1957). The en-
zymes were estimated using standard procedures. 
 
Biochemical estimations  
The livers and hearts were quickly excised 30 h after 
DOX treatment and washed thoroughly with chilled 
phosphate-buffered saline (pH 7.4). The heart and liver 
of each animal was cut into three parts. A 10% tissue 
homogenate of one part of the heart and liver (Sonics 
Vibra-Cell, New Town, CT, USA) was prepared sepa-
rately in 0.15 M Tris–HCl (pH 7.4), centrifuged at 
12000 g for 15 minutes and the supernatant was col-
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lected for the estimation of GSH, CAT, SOD, lipid 
peroxidation (TBARS) and total proteins. The second 
part of heart and liver was homogenized separately for 
the estimation of 8-OHdG DNA adducts, where the 
DNA was isolated as described earlier (Devanaboyina  
& Gupta 1996). The third part of the heart and liver 
was used to prepare a single cell suspension (Klaunig 
et al. 1981, Goldspink et al. 1996) for the estimation of 
PARP activity. 
 
Estimation of DNA adducts 
The DNA adducts were estimated by using 8-OHdG 
Check ELISA Kit, Catalog # KOG-200SE, Gentuar, 
Belgium, according to the manufacturer’s protocol. 
The 8-OHdG kit is a competitive in vitro enzyme-
linked immunosorbent assay for quantitative measure-
ment of oxidative DNA 8-OHdG adducts. The data are 
represented as means ± SEM (standard error of the 
mean) of quadruplicate samples for each drug dose 
from each concurrent group. 
 
PARP assay 
The sample was inoculated into the wells of a mi-
croplate and mixed with PARP reaction buffer (56 mM 
HEPES, 28 mM KCl, 28 mM NaCl, and 2 mM 
MgCl2) containing 0.01% digitonin and 10 µM bioti-
nylated NAD. The microplates were incubated at 37°C 
for 30 minutes. Thereafter, the buffer was aspirated 
and cells were fixed for 10 minutes by the addition of 
prechilled 95% ethanol at -20°C. Endogenous peroxi-
dase activity was blocked by addition of 0.5% hydro-
gen peroxide/methanol into each well followed by 15 
minutes of incubation. Wells were washed once with 
PBS and then blocked with 1% BSA in PBS for 30 
minutes at 37°C. BSA was replaced by the addition of 
peroxidase-labeled streptavidin (diluted 1:500 in 1% 
BSA-PBS) and incubated for 30 minutes at 37°C. 
Thereafter, the microplates were washed three times 
with PBS and the reaction was developed. The optical 
density was measured in a microplate spectrophotome-
ter (BioTek Instruments, Inc., Winooski, VT, USA).  
 
Total proteins 
The protein contents were determined using the modi-
fied method of Lowry. 
 
Glutathione 
GSH concentration was measured by the method of 
Moron et al. (1976). Briefly, proteins were precipitated 
by 25% TCA, centrifuged and the supernatant was col-
lected. The supernatant was mixed with 0.2 M sodium 
phosphate buffer (pH 8.0) and 0.06 mM DTNB and 
incubated for 10 minutes at room temperature. The 
absorbance of the sample/s was read against the blank 
at 412 nm in a UV-VIS double beam spectrophotome-
ter (Shimadzu Corporation, Tokyo, Japan) and the 
GSH concentration was calculated from the standard 
curve.  
 
Catalase 
The catalase activity was estimated by catalytic reduc-
tion of hydrogen peroxide as described earlier (Abei 
1969). Briefly, cumene hydroperoxide was added to 
the sample and incubated at 37°C. The decomposition 
of hydrogen peroxide was monitored by recording the 
absorbance at 240 nm using a UV-VIS double beam 
spectrophotometer.  
 
Superoxide dismutase 
Total SOD activity was determined by the pyrogallol 
autooxidation method (Marklund & Marklund, 1974). 
Briefly, the sample was added to 62.5 mM tris-
cacodylic acid buffer, containing 1 mM diethylenetria-
minepentaacetic acid (DETAPA), followed by the ad-
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Treatment 
Serum enzyme levels (IU/ml) ±SEM 
CK-MB LDH GOT GPT 
Control 7.24±0.538 131.92±2.3 34.03±1.39 9.73±0.79 
2.5 mg/kg NIN 7.62±0.410 139.1±2.15 34.31±2.50 11.04±0.70 
5 mg/kg NIN 6.98±0.21 128.0±3.12 35.6±1.24 9.45±0.22 
7.5 mg/kg NIN 8.12±0.14 129.0±4.12 32.14±2.52 10.50±0.55 
10 mg/kg NIN 6.54±0.54 135.0±5.68 30.44±1.98 8.97±0.44 
DDW + DOX 32.99±0.93c 377.2±4.11c 85.83±1.94c 21.55±0.97c 
2.5 mg/kg NIN + DOX 21.57±0.54 256.5±9.56 68.30±3.21 20.54±0.98 
5 mg/kg NIN + DOX 16.24±0.24 200.2±8.47 59.87±4.21 16.54±1.44 
7.5 mg/kg NIN + DOX 13.43±1.32a 191.8±4.02b 45.43±2.11b 15.03±0.17c 
10 mg/kg NIN + DOX 13.58±1.44 180.0±5.23 45.57±2.54 16.12±1.11 
Table 1. Alteration in various serum enzymes by different doses of naringin in mice treated with 15 mg/kg body weight of 
doxorubicin (DOX). Data are mean ± standard error of the mean (SEM) of four animals. a = p < 0.05, b = p < 0.01 and c = p < 
0.001, when compared with control. 
dition of 4 mM pyrogallol. The autooxidation of pyro-
gallol was monitored at 420 nm using a UV-VIS dou-
ble beam spectrophotometer. 
 
Lipid peroxidation (LOO) 
LOO was performed according to the standard proto-
col (Gelvan & Saltman 1990). Briefly, the samples 
were incubated with a mixture of trichloroacetic acid 
(15%), thiobarbituric acid (0.375%) and butylated hy-
droxytoluene (0.01%) in 0.25 N HCl at 95°C for 25 
min. The reaction mixture was allowed to cool to room 
temperature and was centrifuged at 8,000 g. The super-
natant was then collected and the absorbance was re-
corded using a UV-VIS double beam spectrophotome-
ter. The lipid peroxidation has been expressed as 
TBARS that were determined against a standard curve 
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Figure 1. Alteration in the serum enzymes CK-MB, LDH, GOT and GPT in mice treated with or without naringin before 
doxorubicin treatment. Squares: control group; triangles: NIN + DOX group. P < 0.05 for all points, when compared to control 
or DOX alone compared with NIN + DOX group. 
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were administered p. o. with 10 mg/kg b. wt. NIN 24 
hours after tumor inoculation, once daily, consecu-
tively for 9 days. C) NIN and DOX group: Animals of 
this group were administered orally with 10 mg/kg b. 
wt. NIN, 24 hours after tumor inoculation, and one 
hour before the administration of DOX, once daily 
consecutively for 9 days. 
 After the last administration of drug(s), the 
animals were monitored regularly for body weight 
changes, signs of toxicity and mortality. The animal 
weight was recorded every third day, up to 30 days 
after tumor inoculation in all the groups. The tumor 
response of DOX was assessed on the basis of median 
survival time and tumor free survival. A total of six 
animals were used in each group and a total of 24 ani-
mals were used for this experiment. 
 
Statistical Analysis 
The significance between the treatments was deter-
mined using one way analysis of variance (ANOVA) 
for 8-OHdG, PARP and antioxidant activities, while 
the log rank test was applied for the survival assay. 
The significance between treatments for estimation of 
GSH, and enzymes including CK-MB, LDH, GOT, 
GPT, catalase, SOD and LOO was determined by the 
Students’ ‘T’ test. A p value of <0.05 was considered 
statistically significant. The Solo 4 statistical package 
(BMDP Statistical Software Inc, Los Angeles, CA, 
USA) was used for statistical analyses.  
 
prepared with tetraethoxypropane. For all biochemical 
estimations duplicate samples were used from each 
animal for various estimations listed above. A mini-
mum of four animals were used for each drug dose in 
each concurrent group and a total of forty animals 
were utilized for this experiment. 
 
Effect of NIN in conjuntion with DOX in the tumor 
bearing mice 
A separate experiment was carried out to evaluate the 
effect of NIN on the alteration in the anticancer activ-
ity of doxorubicin in the Ehrlich ascites carcinoma 
(EAC) bearing mice. They were treated with NIN or 
DOX or the combination of both NIN and DOX. 
 Ehrlich ascites carcinoma (EAC) procured 
from Cancer Research Institute (ACTREC), Mumbai, 
India was maintained and propagated by serial intrap-
eritoneal transplantation in an aseptic environment. No 
spontaneous regression of EAC was observed during 
the entire study period. Usually, 106 viable EAC cells 
were injected into each animal intraperitoneally in ster-
ile conditions and the day of tumour inoculation was 
considered as day 0.  
Tumor bearing animals were divided into different 
groups: a) SPS group: Animals of this group received 
sterile physiological saline (SPS) intraperitoneally, 
consecutively for 9 days. DOX group: This group of 
animals was injected with 1.25 mg/kg b. wt. of DOX 
24 hours after tumor inoculation, once daily consecu-
tively for 9 days. B) NIN group: Animals of this group 
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Figure 2. Effect of different doses of NIN on the DOX-induced 8-OHdG DNA adducts in the heart (left) and liver (right) of 
mice. Squares: NIN group; triangles: NIN + DOX group. P < 0.01 for all points, when compared to control or DOX alone com-
pared with NIN + DOX group. 
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Results 
 
Cardioprotection 
Table 1 and Figure 1 show the effect of NIN on DOX-
induced biochemical changes in the serum of mice.  
Treatment of mice with DOX significantly (p<0.001) 
elevated the activities of CK-MB, LDH GOT, and 
GPT indicating that DOX administration induced car-
diotoxicity. The oral administration of various doses of 
NIN once daily for 5 consecutive days before DOX 
treatment significantly inhibited the increase in the 
activities of these enzymes in the serum of mice in the 
"NIN and DOX" group (Table 1 and Figure 1).  
 
DNA adducts 
Spontaneous levels of oxidative DNA adducts (8-
OHdG) were low in heart and liver of non-drug treated 
control group. Treatment of mice with various doses of 
NIN did not significantly alter the spontaneous forma-
tion of 8-OHdG DNA adducts when compared with 
the control group in heart and liver (Figure 2). Admini-
stration of 15 mg/kg DOX significantly (p<0.001) in-
creased the 8-OHdG DNA adduct levels in the heart 
and liver of mice, which was 38- and 65-fold higher in 
the heart and liver, respectively, when compared with 
the non-drug/s treated control group (Figure 2). Pre-
treatment of mice with various doses of NIN once 
daily for five consecutive days before DOX admini-
stration caused a significant and NIN dose dependent 
decline in the levels of 8-OHdG DNA adducts. A 
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maximum reduction in DNA adduct formation was 
observed for 10 mg/kg NIN in the heart and liver when 
compared to the other doses of NIN (Figure 2). This 
reduction in DNA adducts was approximately 2-fold in 
the heart whereas 1.5-fold in the liver of animals re-
ceiving 10 mg/kg NIN before DOX treatment.  
 
PARP 
The ELISA method allows the precise quantification 
of PARP activity. Treatment of mice with various 
doses of NIN did not alter the spontaneous PARP ac-
tivity. Exposure of mice to DOX significantly 
(p<0.001) raised the PARP activity, when compared 
with non-drug treated control group in the heart and 
liver. The PARP activation was almost 9- and 10-fold 
higher in the DOX-treated heart and liver of mice. 
Treatment of mice with various doses of NIN before 
DOX treatment caused a dose dependent decline in the 
PARP activity (Figure 3), when compared with the 
DOX treatment alone. A maximum of 2-fold reduction 
in PARP activity was observed in hearts and livers of 
mice treated with 10 mg/kg NIN before DOX treat-
ment (Figure 3). 
 
Glutathione 
Mice treated with NIN alone did not alter the concen-
tration of GSH when compared with the non-drug 
treated control group. Treatment of mice with DOX 
caused a significant decline (4-fold) in the GSH con-
Figure 3. Effect of different doses of NIN on the DOX-induced PARP activity in the heart (left) and liver (right) of mice. 
Squares: NIN group; triangles: NIN+DOX group. P < 0.001 for all points, when compared to control or DOX alone compared 
with NIN+DOX group. 
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tents in the liver (p<0.001) and heart, whereas treat-
ment of mice with NIN before DOX administration 
significantly elevated the GSH contents in the heart 
and liver in a dose dependent manner and a maximum 
rise in GSH concentration was observed for 10 mg/kg 
NIN before DOX treatment (Figure 4). 
 
Catalase 
Administration of different doses of NIN caused a sig-
nificant elevation in the spontaneous level of catalase 
in the mouse heart and liver, when compared with the 
non-drug treated control group. DOX treatment caused 
a significant (p<0.01) decline in the catalase activity in 
the mouse heart and liver (Figure 5). Treatment of 
mice with different doses of NIN significantly arrested 
the DOX-induced decline in the catalase activity in a 
dose dependent manner in heart and liver. The highest 
increase in catalase activity was observed for 10 mg/kg 
NIN (Figure 5). 
 
Superoxide dismutase 
Treatment of mice with NIN alone elevated spontane-
ous SOD activity significantly (p<0.001), in a dose 
dependent manner in the heart and liver. The greatest 
elevation in SOD activity was observed for 10 mg/kg 
NIN. The DOX treatment caused a significant 
(p<0.001) decline in the spontaneous SOD activity in 
both the heart and liver of mice (Figure 6). Admini-
stration of mice with different doses of NIN before 
DOX treatment caused a significant and NIN dose de-
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pendent elevation in the SOD activity in the heart and 
liver and the greatest increase was observed for 10 mg/
kg NIN in the "NIN and DOX" group (Figure 6).  
 
Lipid peroxidation (LOO) 
The LOO was measured as thiobarbituric acid reactive 
substances (TBARS) in the heart and liver of mice. 
Mice treated with NIN alone did not alter the base lev-
els of TBARS when compared with the non-drug 
treated control group. However, DOX treatment re-
sulted in a significant (p<0.001) elevation in TBARS 
in the heart and liver of mice (Figure 7). The NIN ad-
ministration before DOX treatment caused a signifi-
cant reduction in TBARS in the mouse heart and liver 
in a NIN dose dependent manner and the greatest re-
duction (p<0.001) in the TBARS was observed for 10 
mg/kg NIN in the "NIN and DOX" treatment (Figure 
7). 
 
Effect of NIN in conjunction with DOX in Ehrlich 
ascites carcinoma mice 
The efffect of NIN on the antitumor efficacy of DOX 
was assessed in mice bearing Ehrlich ascites carci-
noma. No spontaneous regression was observed in the 
mouse injected with EAC cells throughout the study 
and the animals exhibited a constant increase in the 
weight due to tumor cell multiplication. The first death 
was observed on day 15 and all the control animals 
died by day 24 post-tumor inoculation. The median 
survival time (MST) and the average survival time 
Figure 4. Alteration in the DOX-induced glutathione concentrations by different doses of NIN in the heart (left) and liver 
(right) of mice. Squares: NIN group; triangles: NIN+DOX group. P < 0.05 for all points, when compared to control or DOX 
alone compared with NIN+DOX group.  
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(AST) were found to be 19.5 and 20.9 days, respec-
tively (Table 2). Treatment of 24 h old tumors with 
1.25 mg/kg DOX inhibited the weight gain in animals 
indicating arrest of tumor cell proliferation and growth 
(Table 2). The DOX treatment increased the MST and 
AST up to 28.5 and 28 days, respectively accompanied 
by an increase in the mean life span (IMLS) and the 
average life span (IALS) up to 46 % and 33 %, respec-
tively. The treatment of 24 h old tumors with 10 mg/kg 
NIN marginally increased the MST (23 days) and AST 
(24 days) when compared with the control group 
(Table 2). However, when the animals were treated 
with 10 mg/kg of NIN and then with 1.25 mg/kg DOX 
a constant retardation in the weight gain was observed, 
indicating arrest of tumor cell multiplication and 
growth (Table 2). However, there was no significant 
alteration in the MST (27.5 days) and AST (27.6 days) 
when compared with the DOX treatment alone (Table 
2). A similar effect was noticed for the increase in 
IMLS and IALS, that was 41% and 32%, respectively 
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(Table 2). A significant increase in survival was seen 
in the animals treated with DOX alone as well as with 
NIN and DOX, when compared with the DDW and 
NIN groups (Figure 8).  
 
Discussion 
 
The clinical use of anticancer anthracyclines is limited 
by the development of a distinctive and life-
threatening form of cardiotoxicity. There are several 
hypotheses to explain DOX-induced cardiotoxicity. 
Among these, the hypothesis implicating the involve-
ment of free radicals is the most widely accepted. 
DOX undergoes one-electron reduction through meta-
bolic activation caused by NADPH-cytochrome-P-450 
reductase, or other flavin-containing enzymes involv-
ing mitochondria (Bachur et al. 1978, Montaigne et al. 
2012). This reduction generates a DOX semiquinone 
free radical, which reacts with the molecular oxygen, 
and reduces it to superoxide, with the regeneration of 
intact DOX. Superoxide is rapidly converted to hydro-
gen peroxide, either spontaneously or with the help of 
superoxide dismutase. The DOX semiquinone can re-
act with hydrogen peroxide to yield a hydroxyl radical 
(Kalyanaraman et al. 1984). These highly toxic reac-
tive oxygen species react with cellular molecules in-
cluding nucleic acids, proteins and lipids and cause 
cell damage. 
 Anthracycline-induced cardiotoxicity has been 
Figure 5. Alteration in the DOX-induced catalase activity by different doses of NIN in the heart (left) and liver (right) of mice. 
Squares: NIN group; triangles: NIN+DOX group. P < 0.05 for all points, when compared to control or DOX alone compared 
with NIN+DOX group. 
Drug dose MST IMLS AST IALS 
DDW 19.5   20.9   
NIN 23 17.9 24 14 
DOX 28.5 46 28 33 
NIN+DOX 27.6 41 27.6 32 
Table 2. Effect of 10 mg/kg body weight naringin on me-
dian survival time (MST) and average survival time (AST) 
of EAC mice treated with DOX. Six animals were used in 
each group (n = 6). 
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observed in 2 to 20% of patients at an early stage 
(Goebel & Kaplan 1992) and the reduction of DOX-
induced cumulative cardiomyopathy represents a ma-
jor goal in improving the clinical application of DOX. 
The iron chelator dexrazoxane (ICRF-187) has been 
shown to protect against doxorubicin induced cardio-
toxicity; however, its clinical applications have been 
limited because of its hematological toxicity (Sparano 
1998, Sepe et al. 2010). The administration of zinc or 
bismuth has also been reported to protect against DOX
-induced myocardial toxicity by the induction of met-
allothionein (Satoh et al. 1998). The action of metal-
lothionein seems to be based on their ability to scav-
enge hydroxyl radicals (Sato & Bremner, 1993). An-
giotensin-converting enzyme inhibitors as well as 7-
monohydroxyethylrutoside have been reported to pro-
tect against DOX-induced cardiotoxicity. The major 
drawback of 7-monohydroxyethylrutoside therapies 
has been the need of relatively high dose to obtain 
complete cardioprotection. Frederine has also been 
found to reduce the DOX-induced cardiotoxicity (Van 
Acker et al. 2001). It is necessary to screen for newer 
paradigms, which can reduce the toxicity of doxorubi-
cin, without compromising its antineoplastic activity. 
Results of the present study demonstrate that NIN has 
been able to reduce the DOX-induced cardiac toxicity 
in mice, which was evident by a significant reduction 
in the serum levels of CK-MB, LDH, GPT and GOT. 
The elevation of serum CK has been reported to be a 
reliable indicator of DOX-induced cardiotoxicity 
(Horacek et al. 2007). In line with this, narigin treat-
ment has been previously reported to reduce DOX-
induced cardiotoxicity (Arafa et al. 2005). Similarly 
curcumin and antarth, a poly herbal preparation, have 
been reported to reduce DOX-induced cardiotoxicity in 
vivo (Venkatesan 1998, Jagetia et al. 2005). Resvera-
trol (another polyphenol) has been reported to reduce 
the DOX-induced elevation in LDH and GOT in Wis-
tar rats (Tatlidede et al. 2009) indicating alleviation of 
cardiotoxicity. 
 ROS can directly bind to DNA forming DNA 
adducts and alkali-labile sites. DNA strand breaks re-
sult following excision repair (Guirouilh-Barbat  et al. 
2008). It is therefore, conceivable that there is a close 
relationship between DNA adduct formation and DNA 
strand breaks. Under normal circumstances, DNA 
damage always takes place but is kept to a minimum 
by the cell’s protective mechanisms that include a rep-
ertoire of antioxidants as well as efficient repair en-
zymes. However, under certain conditions, the fine 
balance between pro-oxidants and the protective 
mechanisms can be upset, resulting in oxidative stress. 
This can adversely affect the integrity of the cellular 
genome. Among the earliest cellular changes are the 
formation of DNA adducts, which are covalent binding 
products of oxidants with chemicals. These are formed 
when a DNA molecule is exposed to a pro-oxidant 
species. The DNA adducts could inhibit gene tran-
scription on three different levels: a) by inhibiting 
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Figure 6. Alteration in the DOX-induced superoxide dismutase activity by different doses of NIN in the heart (left) and liver 
(right) of mice. Squares: NIN group; triangles: NIN+DOX group. P < 0.001 for all points, when compared to control or DOX 
alone compared with NIN+DOX group.  
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DNA binding proteins through steric constraints, ren-
dering DNA unrecognizable due to adduct-induced 
bending, or through subsequent mutation of the DNA 
bases required in the consensus sequence (Broggini & 
D'Incalci 1994, Pointon et al. 2010); b) by inhibiting 
the potential of the DNA to bend into the required con-
formation to bring distant regions together and initiate 
transcription (van der Vlet & Verrijzer 1993); and c) 
by posing a direct blockage to the path of RNA poly-
merase (Cullinane & Phillips, 1990, Cutts et al. 1994). 
Overall, the extent of inhibition of transcription facili-
tated by DNA adducts is potentially much greater. The 
possibility to determine specific DNA adducts quanti-
tatively, and their comparison to other genotoxic pa-
rameters or biomarkers provides essential information 
on the mechanisms of potentially genotoxic agents. 
DNA adducts are of greater significance with respect 
to mutagenic or carcinogenic outcomes, and their role 
in mutagenesis is well documented (Vrtis et al. 2013). 
 Treatment of mice with various doses of DOX 
induced a significant and dose dependent increase in 8-
OHdG in the heart and liver. A similar effect has been 
reported earlier, where doxorubicin treatment has been 
reported to induce 8-OHdG and mtDNA adducts in 
rats (Serrano 1999, Palmeira 1997, Zhou et al. 2001). 
Similarly, DOX treatment has been found to increase 
the DNA adducts in patients (Dorshow et al. 2001). A 
concentration dependent rise in DNA adduct formation 
has been observed in MCF-7 cells exposed to DOX 
(Coldwel et al. 2008). Increased levels of 8-OHdG in 
the genomic DNA indicate DOX-induced oxidative 
damage. Pre-treatment of mice with various doses of 
NIN significantly reduced the levels of 8-OHdG in the 
heart and liver, when compared with the DOX group. 
Reports on the DOX-induced DNA adducts inhibition 
by NIN are unavailable. However, Resvreratrol has 
been reported to increase DNA adduct formation in 
DOX treated rats (Tatlidede et al. 2009). The alcohol 
free beer has been found to reduce DOX-induced DNA 
adducts (Valls-Belles et al. 2008). 
 PARP activation has been indicated in DOX-
induced toxicity (Pacher et al. 2002). Over activation 
of PARP leads to tissue damage in various pathophysi-
ological conditions associated with increased oxidative 
stress, including myocardial reperfusion injury as well 
as drug-induced cardiomyopathy (Pacher et al. 2002, 
Do & Chen 2013). DOX-treatment caused an overacti-
vation of PARP in the mouse heart and liver, in the 
present study. A similar effect has been reported ear-
lier in BALB/C mice treated with DOX (Patcher et al. 
2002). Over activation of PARP is a hallmark of DOX-
induced genomic damage. NIN significantly inhibited 
the DOX induced PARP synthesis in a dose dependent 
manner indicating that NIN protected the genome 
against DOX-induced insult and cardiotoxcity. PJ-34 
has been reported to inhibit the activity of PARP in-
duced by DOX. Pharmacological inhibition of PARP 
with PJ-34 has been reported to attenuate the DOX-
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Figure 7. Alteration in the DOX-induced lipid peroxidation by different doses of NIN in the heart (left) and liver (right) of 
mice. Squares: Control group; triangles: NIN+DOX group. P < 0.001 for all points, when compared to control or DOX alone 
compared with NIN+DOX group. 
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induced toxicity (Pacher et al. 2002, Szenczi et al. 
2005, Magan et al. 2012). Similarly, AG014699 and 
tannic acid have been reported to inhibit PARP activity 
and reduce DOX-induced cardiotoxicity earlier (Ali et 
al. 2011, Tikoo et al. 2011).  
 It is clinically undesirable for the antitumor 
activity of DOX to be weakened by combining it with 
other pharmacological agents that protect against its 
cardiotoxicity. Therefore, we examined the influence 
of NIN on the antitumor activity of DOX in tumor 
bearing mice. The studies on EAC tumor bearing mice 
indicate that NIN treatment did not interfere with the 
antitumor activity of DOX as the MST and AST in the 
NIN and DOX-treated group remained unchanged 
when compared with the non-NIN treated controls. A 
similar effect was also discernible in the tumor bearing 
animals that received antarth before each DOX-
treatment earlier (Jagetia et al. 2005). Our study dem-
onstrates that use of NIN with DOX may be a good 
paradigm for tumor therapy, since NIN does not inter-
fere with the antineoplastic activity of DOX and, at the 
same time, it also reduces cardiac and hepatic toxici-
ties induced by DOX. Despite these encouraging re-
sults, it may be premature to look into the clinical im-
plications of our findings since more detailed studies 
are required in different tumor models and the mecha-
nisms responsible for reduced DOX-induced cardio-
toxicity by NIN need to be elucidated. 
 The exact mechanism of cardioprotection by 
NIN is not known; however, it may have used multiple 
mechanisms to exert its cardioprotective effects against 
DOX-induced caridotoxicity in the present investiga-
tion. DOX-induces free radical generation and elevates 
oxidative stress in the heart leading to cardiotoxicity 
(DeAtley et al. 1999, Gewirtz 1999). Therefore, inhibi-
tion of free radical generation by NIN in DOX-treated 
animals may be one important mechanism of its action. 
NIN has been reported to inhibit free radical genera-
tion in vitro (Jagetia et al. 2003). The increase in anti-
oxidants by NIN in the DOX-treated group may be 
another mechanism by which NIN has reduced the 
DOX-induced cardiotoxicity. This contention is sup-
ported by the observation that NIN treatment before 
DOX-administration raised superoxide dismutase, 
catalase and GSH and reduced lipid peroxidation, 
which may be due to the upregulated gene expression 
of these enzymes. In line with this, an upregulation of 
mRNA expression of SOD, catalase and GSHPx has 
been reported by NIN-supplementation earlier (Jeon et 
al. 2001). The administration of NIN has reduced 
DOX-induced DNA adduct formation and inhibited 
the PARP activity, which may have also contributed to 
the alleviation of cardiotoxicity. NIN has been reported 
to chelate iron and this activity may have also been 
responsible for its effects in this study. Furthermore, 
DOX has been reported to increase the activation of 
NF-κB in cultured cardiomyocytes. Inhibition of NF-
κB by NIN may have inhibited the inflammation and 
thereby reduced DOX-induced cardiotoxicity (Guo et 
al. 2013, Li et al. 2013). 
 Our study indicates that NIN alleviated cardio-
toxicity in mice treated with DOX by inhibiting PARP 
activity and reducing the DNA adduct formation, scav-
enging of free radicals, increasing oxidant status and 
reduced lipid peroxidation. NIN may have also sup-
pressed the NF-κB activation in the heart of mice re-
ceiving DOX. 
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